Table II.
KRAS mutation status according to patient and tumor characteristics.
| Characteristic | Total, n | WT KRAS, n (%; n=53) | MT KRAS, n (%; n=51) | P-value |
|---|---|---|---|---|
| Sex | 0.015 | |||
| Male | 61 | 37 (60.6) | 24 (39.4) | |
| Female | 43 | 16 (37.2) | 27 (62.8) | |
| Age, years | 0.180 | |||
| <60 | 34 | 20 (58.8) | 14 (41.2) | |
| ≥60 | 70 | 33 (47.2) | 37 (52.8) | |
| ECOG | 0.069 | |||
| 0 | 38 | 24 (63.2) | 14 (36.8) | |
| 1-2 | 66 | 29 (43.9) | 37 (50.1) | |
| Tumor localization | 0.001 | |||
| Right colon | 20 | 3(15) | 17(85) | |
| Left colon | 48 | 27 (56.2) | 21 (43.8) | |
| Rectum | 36 | 23 (63.9) | 13 (36.1) | |
| Charlson index | 0.550 | |||
| ≤8 | 53 | 29 (54.7) | 24 (45.3) | |
| >8 | 51 | 24(47) | 27(53) | |
| T stage | 0.310 | |||
| T2-3 | 70 | 34 (48.6) | 36 (51.4) | |
| T4 | 34 | 19 (55.9) | 15 (44.1) | |
| N stage | 0.270 | |||
| N negative | 19 | 8 (42.1) | 11 (57.9) | |
| N positive | 85 | 45(53) | 40(47) | |
| Treatment program | 0.020 | |||
| Surgery first | 60 | 36(60) | 24(40) | |
| Chemotherapy first | 44 | 17 (38.6) | 27 (61.4) | |
| Primary tumor resection | 0.460 | |||
| Yes | 74 | 37(50) | 37(50) | |
| No | 30 | 16 (53.3) | 14 (46.7) | |
| Lung metastases | 0.530 | |||
| Absent | 85 | 43 (50.6) | 42 (49.4) | |
| Present | 19 | 10 (52.6) | 9 (47.4) | |
| Resection/local treatment hepatic metastases | 0.016 | |||
| No | 76 | 35(46) | 41(54) | |
| Yes | 28 | 19 (67.9) | 9 (32.1) | |
| Grade of differentiation | 0.460 | |||
| Well-moderately differentiated | 85 | 44 (52.8) | 41 (48.2) | |
| Poorly differentiated | 19 | 9 (47.3) | 10 (52.7) | |
| CEA, ng/ml | 0.300 | |||
| ≤10 | 30 | 17 (56.6) | 13 (43.4) | |
| >10 | 74 | 36 (48.7) | 38 (51.3) | |
| CA19-9, U/l | 0.009 | |||
| ≤37 | 48 | 31 (64.5) | 17 (35.5) | |
| >37 | 56 | 22 (39.3) | 34 (60.7) | |
| GOT, U/l | 0.280 | |||
| <34 | 63 | 34(54) | 29(46) | |
| >34 | 41 | 19 (46.3) | 22 (53.7) | |
| AF, U/l | 0.420 | |||
| ≤120 | 55 | 29 (52.7) | 26 (47.3) | |
| >120 | 49 | 24(49) | 25(51) |
A χ2 test was used to calculate the P-values. CEA, carcinoembryonicantigen; CA19.9, carbohydrate antigen 19-9; GOT, glutamic oxalacetic transaminase; ECOG, Eastern Cooperative Oncology Group performance status; AF, alkaline phosphatase.